In market access, the era of digital value communication has dawned

As the initial waves of the coronavirus pandemic hit in early 2020, pharma and biotech stocks saw major declines as investors digested the likely impact.

Executives worried, with good reason, that restrictions on travel and social mixing would have a chilling impact on the face-to-face interactions that are so important to the development and commercialization of new medicines.

But the second half of the year pointed to a more positive outlook, as stocks recovered, and the industry began to find its feet.